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Abstract 
Fed-batch Chinese hamster ovary (CHO) cell culture is the most commonly used process for IgG 
production in the biopharmaceutical industry. Amino acid and glucose consumption, cell growth, 
metabolism, antibody titer and N-glycosylation patterns are always the major concerns during 
upstream process optimization, especially media optimization. Gaining knowledge on their 
interrelations could provide insight for obtaining higher immunoglobulin G (IgG) titer and better 
controlling glycosylation-related product quality. In this work, different fed-batch processes with 
two chemically defined proprietary media and feeds were studied using two IgG-producing cell 
lines. Our results indicate that the balance of glucose and amino acid concentration in the culture is 
important for cell growth, IgG titer and N-glycosylation. Accordingly, the ideal fate of glucose and 
amino acids in the culture could be mainly towards energy and recombinant product, respectively. 
Accumulation of by-products such as NH4
+
 and lactate as a consequence of unbalanced nutrient 
supply to cell activities inhibits cell growth. The levels of Leu and Arg in the culture, which relate 
to cell growth and IgG productivity, need to be well controlled. Amino acids with the highest 
consumption rates correlate with the most abundant amino acids present in the produced IgG, and 
thus require sufficient availability during culture. Case-by-case analysis is necessary for 
understanding the effect of media and process optimization on glycosylation. We found that in 
certain cases the presence of Man5 glycan can be linked to limitation of UDP-GlcNAc biosynthesis 
as a result of insufficient extracellular Gln. However, under different culture conditions, high Man5 
levels can also result from low α-1,3-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase 
(GnTI) and UDP-GlcNAc transporter activities, which may be attributed to high level of NH4
+
 in 
the cell culture. Furthermore, galactosylation of the mAb Fc glycans was found to be limited by 
UDP-Gal biosynthesis, which was observed to be both cell line and cultivation condition-dependent. 
Extracellular glucose and glutamine concentrations and uptake rates were positively correlated with 
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intracellular UDP-Gal availability. All these findings are important for optimization of fed-batch 
culture for improving IgG production and directing glycosylation quality. 
 
Introduction 
In recent decades, the annual global market of recombinant therapeutic proteins has grown 
significantly from ca. $12 billion in the year 2000 to $33 in 2004 and $99 billion in 2009 (Walsh 
2003; Walsh 2006; Walsh 2010). Monoclonal antibodies (mAbs), in particular, which offer novel 
therapy avenues for cancer, inflammatory diseases, infectious diseases and autoimmune diseases, 
have had remarkable success in both regulatory approval and global sales (Jimenez Del Val et al. 
2010; O'Callaghan and James 2008). Chinese Hamster Ovary (CHO) cells are extensively used for 
the production of recombinant antibodies as a result of their robust growth and the potential to 
produce non-immunogenic antibodies with glycosylation patterns similar to humans (Jefferis 2007; 
Raju 2003). N-linked glycosylation plays a critical role in the biological properties of therapeutic 
IgG, e.g. effectors function, immunogenicity, stability, and clearance rate (Burton and Dwek 2006; 
Goochee et al. 1991; Jefferis 2009a; Jefferis 2009b; Raju 2008). Therefore, control of glycosylation 
is of prime importance to meet regulatory requirements and for quality compliance. Naturally 
occurring IgG have two conserved N-glycosylation sites at Asn
297
 with the consensus sequence 
Asn-X-Ser/Thr on the heavy chains, where X is any amino acid except Pro. The heterogeneity of 
the glycan structures on each glycosylation site can vary according to their biosynthetic stage from 
less mature forms (e.g. non-glycosylated and high mannose forms) to more mature forms (e.g. 
galactosylated and sialylated forms).  
The process of N-glycosylation, although complicated, has been well characterised (Kornfeld and 
Kornfeld 1985). Initially in the endoplasmic reticulum (ER), a lipid-linked oligosaccharide 
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precursor (Glc3Man9GlcNAc2-PP-dolichol) is synthesized by transferring N-acetylglucosamine, 
mannose and glucose residues from UDP-GlcNAc, GDP-mannose and UDP-glucose (the nucleotide 
sugars synthesized in cytosol and transported into ER), respectively, to a lipid carrier, dolichol 
phosphate.  These precursors are subsequently transferred to the available N-glycosylation sequons 
present on the nascent polypeptide chain. The three glucose residues present on the now protein-
bound oligosaccharide contribute to protein folding via the calnexin-calreticulin cycle. After the 
cycle has ensured adequate protein folding, all three glucose residues are cleaved from the 
oligosaccharide (Ellgaard and Helenius 2003). Then, one mannose residue is trimmed in the ER 
prior to the IgG being translocated to the Golgi apparatus by means of vesicles (Hossler et al. 2009). 
In the Golgi, the N-linked glycans mature in a step-wise fashion through a number of enzyme-
catalyzed reactions where monosaccharide residues are trimmed off or added to the carbohydrate 
structure. The maturation of glycans is largely dependent on factors such as expression, activity and 
localization of the glycosidase and glycosyltransferase enzymes (Jassal et al. 2001; Kanda et al. 
2006; Mori et al. 2004; Paulson and Colley 1989; Weikert et al. 1999), the intracellular levels and 
availability of nucleotides and nucleotide sugars, e.g. GDP-Man, UDP-GlcNAc, UDP-Glc, and 
UDP-Gal (Baker et al. 2001; Hills et al. 2001; Nyberg et al. 1999), and the accessibility of 
glycosylation sites on the glycoprotein (Holst et al. 1996 ). For example, the Man5 glycans can 
remain unprocessed due to insufficient -mannosidase II (ManII)  activity or when the GlcNAc 
addition reaction is limited by insufficient availability of intracellular UDP-GlcNAc or low α-1,3-
mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase (GnTI)  activity (Pacis et al. 2011). 
Glycolysis and glutaminolysis are the key metabolic pathways of CHO cells (Quek et al. 2010). 
Through glycolysis, CHO cells consume glucose as the main carbon source for energy production 
and generate lactate as the most common metabolic by-product. Glutaminolysis is the prevalent 
pathway through which CHO cells assimilate organic nitrogen for biomass synthesis while releasing 
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ammonium as the main by-product (Altamirano et al. 2006; Lu et al. 2005). Fed-batch culture is 
widely used for the production of recombinant antibodies in industry (Huang et al. 2010). In fed-
batch culture, periodic delivery of appropriate feeds provides sufficient nutrients to support cell 
growth and metabolism and induce a prolonged and productive culture life (Chee Furng Wong et al. 
2005). However, accumulation of cellular by-products may inhibit cell growth, threaten culture 
longevity, reduce antibody production and compromise antibody glycosylation (Chen and Harcum 
2005; Dorai et al. 2009; Gawlitzek et al. 2000; Hossler et al. 2009; Li et al. 2012). Understanding 
the interplay between cell growth, cell metabolism, IgG synthesis and glycosylation and how these 
factors vary among different cell lines and media composition at the metabolic level will benefit 
bioprocess optimization, media development and will be useful in identifying screening and 
engineering targets (Dean and Reddy 2013). 
Aiming at high titer production and adequate glycosylation-related quality of IgG, different 
strategies have been proposed to improve CHO cell culture performance. Limiting the feed of 
glucose (Cruz et al. 1999; Gagnon et al. 2011; Gambhir et al. 1999) and glutamine (Chee Furng 
Wong et al. 2005),  substituting glucose (Altamirano et al. 2006; Altamirano et al. 2004) and 
glutamine (Altamirano et al. 2001; Altamirano et al. 2000) with alternative nutrients, addition of 
feed supplements (Gramer et al. 2011),  optimization of process parameters such temperature, pH, 
agitation rate and osmolality (Ahn et al. 2008; Fox et al. 2004; Pacis et al. 2011; Senger and Karim 
2003; Trummer et al. 2006) and engineering of metabolic (Fogolin et al. 2004; Kim and Lee 2007; 
Zhou et al. 2011) and anti-apoptotic  (Druz et al. 2013; Mastrangelo et al. 2000) targets have all 
been attempted. In addition, many efforts have been made on metabolic profiling (Jimenez Del Val 
et al. 2011; Kochanowski et al. 2008; Sellick et al. 2011), and 
13
C metabolic flux analysis (Ahn and 
Antoniewicz 2011; Dean and Reddy 2013; Quek et al. 2010) of CHO cell culture at different 
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growth stages to further understand the interplay between energy, cell growth, protein production 
and glycosylation in CHO cells. 
Herein, we present the differences in cell growth, IgG production, nutrient consumption, 
intracellular nucleotide sugar availability and IgG glycosylation for two IgG-producing cell lines 
grown in fed-batch cultures with two different chemically-defined proprietary media and feeds. Our 
results provide an integrative approach to understand the relationship of glucose and amino acid 
metabolism, nucleotide sugar metabolism, cell growth, IgG production and glycosylation in fed-
batch CHO cell culture and give guidance for future process optimization and media development 
from a metabolic point of view. 
 
Material and Methods 
Cell lines and media 
Two Symphogen in-house IgG1-producing CHO cell lines (1030 and 4384) were used in this study. 
Both of them were generated from a dihydrofolate reductase-deficient (DHFR-) CHO DG44 cell 
line (Urlaub et al. 1983) through methotrexate (MTX) mediated stable transfection with a vector 
containing DHFR and the genes for antibody heavy and light chains, followed by fluorescence 
activated cell sorting (FACS) and adaptation to serum-free medium. All basal media and feeds used 
in this study are proprietary, chemically defined and serum-free. Cells were maintained and 
expanded in basal media B in shake flask at 200rpm in a 37˚C humidified culture incubator supplied 
with 5% CO2.  
Fed-batch culture  
Cells were seeded at a density of 5 ×10
5
 viable cells/ ml for a 2-day passage or 3 ×10
5
 viable cells/ 
ml for a 3-day passage prior to the inoculation of fed-batch cultures.  Cells in fed-batch culture were 
grown in 500 ml shake flasks with an initial culture volume of 70ml at 37°C, 5% CO2, 200rpm. The 
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temperature was shifted from 37°C to 33.5°C on day 5. All sampling was carried out before feeding. 
The culture was harvested when the viability became lower than 60% or on day 14. Viability and 
viable cell density (VCD) was measured by Vi-CELL XR (Beckman Coulter, Brea, CA). Glucose, 
glutamine, lactate, ammonium, glutamate, pH and osmolality were measured by Bioprofile 100plus 
(Nova BioMedical, Waltham, WA). IgG titer was determined by biolayer interferometry using Octet 
QK384 equipped with Protein A biosensors (ForteBio, Menlo Park, CA) according to the 
manufacturer's instructions.  
Duplicates of different fed-batch cultures for the 1030 and 4384 cell lines were carried out in two 
different basal media A and B with the corresponding feed media FA and FB.  
In the A+FA8  culture (basal media A, feed FA, seeding density at 8×10
5
 viable cells/ml), the 1030 
or 4384 cells were initially seeded at 8×10
5
 viable cells/ml in basal media A. Feed FA (3.3% of the 
initial culture volume) was added to the culture once a day from day 2 onwards. Glucose was 
adjusted to 8g/L on days 5 and 7, 10g/L on days 9 and 11. Cell culture was sampled on days 2, 5, 7, 
9, 11 and 13 for measuring cell growth, metabolism and IgG expression. Additional sampling for 
nucleotide sugar measurement was performed on days 2, 5, 9 and 11 and for western blot analysis 
on days 2 and 11. Samples for amino acid analysis were taken from the 4384 cell culture on days 5, 
7, 11 and 13. The culture was harvested on day 13 according to viability criteria. 
Only the 1030 cells were tested in the A+FA4 cultivation condition. The A+FA4 culture use same 
basal media and feed as the A+FA8 culture, but with a different seeding density of 4×10
5
 viable 
cells/ml. The feeding strategy is also same as the A+FA8 process. However, no glucose addition 
was required in the process. Cell culture was sampled on days 2, 5, 7, 9 and 12 for cell growth, 
metabolism and IgG expression measurement and was harvested on day 12 according to viability 
criteria. 
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The B+FB4 culture (basal media B, feed FB, seeding density at 4×10
5
 viable cells/ml) started with 
an initial culture (cells in basal media B with 13% initial culture volume of feed FB) at a seeding 
density of 4×10
5
 viable cells/ml. Feed FB (10% of the initial culture volume) was added to the 
culture on days 2, 5, 7, 9 and 11. For the 1030 cell line, glucose was adjusted to 6g/L on day 5 and 9 
g/L on days 9 and 11. For the 4384 cell line, glucose was added as described above for the 1030 cell 
line, although it was adjusted to 10g/L on day 9. Cell culture was sampled on days 2, 5, 7, 9, 11, 13 
and 14 for measuring cell growth, metabolism and IgG expression. Additional sampling for 
intracellular nucleotide sugar quantification was carried out on days 2, 5, 9 and 11 and for western 
blot analysis on days 2 and 11. For the 4384 cell line, cell culture was also sampled for amino acid 
analysis on days 5, 7, 11 and 13. Fed-batch culture was harvested on day 14. 
 
Free amino acid analysis 
Samples from cell culture were clarified by centrifugation at 4500rpm for 3min. To precipitate and 
remove remaining proteins, 30 µl 4% sulphosalic acid (Sigma-Aldrich, St. Louis, MO) were added 
into 30 µl clarified sample of the supernatant. After centrifugation (12,000g, 5min), 20µl of the 
resulting suspension was collected and dried using a SpeedVac (Thermo Scientific, Waltham, MA). 
The dried samples were resuspended in 160µl of start buffer, containing 0.2M Trisodium citrate 
dihydrate (Sigma-Aldrich) and 0.65% v/v HNO3 (Sigma-Aldrich) with pH =3.1 prior to injection 
into the amino acid analyzer system. The system controlled by Millennium32 software (Waters, 
Milford, MA) is composed of two M510 pumps (Waters), two regent manager pump (Waters), a 
M717 refrigerated autosampler (Waters), a M474 fluorescence detector (Ex= 338 nm, Em= 455 nm) 
(Waters), a column oven (Waters), and a MCI-Gel CK10U column (Mitsubishi Chemical industries, 
Japan). All chemicals used to prepare the relevant solvents and reagents are purchased from Sigma-
Aldrich. Amino acid analysis was performed using cation-exchange chromatography followed by 
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postcolumn derivatization and fluorescence detection. Eluents used were solvent A (0.2M 
Trisodium citrate dihydrate, 0.05% v/v phenol and 5% v/v isopropanol, pH adjusted to 3.1 with 
nitric acid) and solvent B (0.21M sodium borate, 5% v/v isopropanol, pH adjusted to 10.2 with 
NaOH). Eluents were prepared freshly and filtered by 0.2 µm filter units (Nalgene, Thermo 
Scientific). Chromatography was carried out using a flow rate at 0.32ml/min and a column 
temperature at 62°C with the following gradient: T0 min =0% B, T15 min=10% B, T28 min=40% B, T36 
min =50% B, T40 min = 100% B, T52 min = 100% B, T53 min = 0% B. Post column oxidation and 
derivatization sequentially took place at 62°C in a 50cm 0.22mm i.d. coil with flow of hypoclorite 
reagent (flow rate = 0.3ml/min) and a 150cm 0.5mm coil with a flow of OPA reagents (flow rate = 
0.3ml/min). Hypochlorite and OPA reagents can be prepared as described in (Barkholt and Jensen 
1989). Peak assignment and integration was done automatically with a user-defined data processing 
method.  
Specific metabolic rate 
The concentration of a certain nutrient or metabolite in the cell culture before feeding (Cx before) was 
measured as described above. Moreover, the concentration after feeding (Cx after) was calculated 
based on the culture volume and known addition of the proprietary feed at that time point. 
Additionally, the specific consumption or production rate of certain nutrient or metabolite (qx) from 
time point t1 to time point t2 was calculated from the following equation: 
    
         
          
  
           
 , in which IVC is the integral of viable cell density. 
Nucleotide sugar analysis 
Cell pellets from 2ml cell culture samples were collected and washed with 2ml ice-cold 0.9% w/v 
aqueous NaCl (Sigma-Aldrich) by centrifugation (0°C, 1000g, 1min). They were flash-frozen in 
liquid nitrogen and stored at -80°C until acetonitrile extraction. Under acetonitrile extraction, they 
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were then resuspended and incubated in ice-cold 50% v/v aqueous acetonitrile (Sigma-Aldrich) on 
ice for 10 min prior to centrifugation (0°C, 18,000g, 5min). Collected supernatant was dried in a 
SpeedVac (Savant, Thermo Scientific), resuspended in 240µl water and store at -80°C until 
applying on HPLC for high-performance anion-exchange (HPAEC) analysis as describe in  
(Jimenez Del Val et al. 2013).  
IgG purification 
Harvested cell culture was centrifuged at 4500g for 20 min using Multifuge 3SR (Hereaus, Thermo 
Scientific). The supernatant was filtered through a 0.22 μm filter (Millipore, Billerica, MA) prior to 
application onto the self-packed MabSelect SuRe ProteinA column, which contains 200 μl of 
MabSelect SuRe protein A resin slurry (GE Healthcare, Fairfield, CA) equilibrated with PBS.  IgG 
was captured by the column and eluted by 500 μl of 0.1 M citrate with pH=3.5. The elution was 
immediately subjected to a buffer exchange procedure by passing through a NAP-5 column (GE 
Healthcare) equilibrated by a formulation buffer containing 10 mM Citrate (Sigma-Aldrich) and 
150 mM NaCl (Sigma-Aldrich)  with pH =6.0. IgG concentration was measured using NanoDrop 
ND-1000 (Thermo Scientific). Purified IgG was stored at -20°C until further analysis. 
Intact mass analysis of IgG 
Intact mass analysis of the purified IgG was performed on a LC-MS system using Dionex Ultimate 
3000 RSLC System equipped with Ultimate 3000 RS variable wavelength detector (Dionex, 
Sunnyvale, CA) and Mass Prep micro desalting 2.1x5mm column (Waters) in conjunction with 
micrOTOF-Q II (Bruker, Billerica, MA). The flow rate was 0.2ml/min. The gradient with solvent A 
(water with 0.1% formic acid; Sigma-Aldrich) and solvent B (acetonitrile with 0.1% formic acid; 
Sigma-Aldrich) was as follow:  T0 min = 5% B, T2 min= 5% B, T2.1min= 90% B T5 min = 90% B, T5.1 min 
= 30% B, T6 min = 30% B, T7 min = 90% B, T7.1 min = 5%, T11 min = 5%. The UV detection was 
performed at 215nm. The different combinations of glycans on the IgG was analyzed and quantified 
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according to the peak intensity of each isoform in the intact mass spectrum of IgG using Bruker 
Compass Data Analysis 4.2 software (Bruker).                                                                                                                                                            
Glycoprofiling of IgG 
IgG glycoprofiling was carried out using GlykoPrep® InstantAB™ kit (Prozyme, Hayward, CA) 
for quantifying the total of each N-glycans. Digestion, labeling and cleanup of N-glycans from IgG 
was performed according to the manufacturer's instructions. Labeled glycans were buffered in 50% 
v/v aqueous acetonitrile prior to the HPLC analysis using Dionex Ultimate 3000 RSLC System 
equipped with Ultimate 3000 RS fluorescence detector (Dionex) and ACQUITY UPLC BEH 
Glycan 1.7 μm, 2.1 x 150 mm column (Waters). The mobile phase used was solvent A (100% 
acetonitrile; Sigma-Aldrich) and solvent B (100mM ammonium formate with pH= 4.5; BDH-Merck, 
Poole, UK). Elution of the sample was performed using the following flow rate and gradient: T0 min 
= 25% B with flow rate = 0.5 min/ml, T5 min= 25% B with flow rate = 0.5 min/ml, T51.5 min= 40% B 
with flow rate = 0.5 min/ml, T53 min = 100% B with flow rate = 0.25 min/ml, T58 min = 100% B with 
flow rate = 0.25 min/ml, T60 min = 25% B with flow rate = 0.5 min/ml, T70 min = 25% B with flow rate 
= 0.5 min/ml, T75 min = 25% B with flow rate = 0.5 min/ml. Fluorescence detection were performed 
at Ex= 278nm and Em = 344nm. Analysis of the chromatogram was performed with Chromeleon 
software (Dionex). Relative quantification was performed using peak area and peak assignment 
based on retention time of known standards. 
Western blot analysis 
Cell pellets from culture samples were washed with PBS (Invitrogen, Life Technologies, Carlsbad, 
CA) and lysed in RIPA buffer (Thermo scientific) in the presence of protease inhibitor cocktail 
(Thermo scientific) on ice. The lysates were sonicated and centrifuged for 2 min at 14000 G. Total 
protein concentration in the collected supernatant was quantified by pierce BCA protein assay kit 
(Thermo scientific). NuPAGE sample loading buffer and reducing buffer (Invitrogen, Life 
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Technologies) were added as required for each supernatant sample containing same amount of total 
protein. Samples were heated at 90°C for 10 min prior to loading onto NuPAGE 4-12% Bis-Tris gel 
(Invitrogen, Life Technologies). Electrophoresis was run at 150V for 1 h using MES buffer 
(Invitrogen, Life Technologies). Proteins were transferred to nitrocellulose membrane using iBlot 
system (Invitrogen, Life Technologies). Membrane was blocked in Odyssey blocking buffer (LI-
COR) for 1 h (room temperature, 50rpm), probed with goat anti-MGAT1 antibody (1:1000; Abcam, 
Cambridge, UK) and rabbit anti-SLC35A3 antibody (1:1000; Abcam) and rabbit anti β-actin 
antibody (1:1000; Cell Signaling, Danvers, MA) over night (4°C, 50rpm) and washed with TBS 
(BioRad, Hercules, CA) with 0.1% Tween 20 (Millipore, Billerica, MA). After 1 h incubation 
(room temperature, 50rpm) with IR Dye 800 CW-conjugated donkey anti-goat and anti-rabbit 
antibody (1:5000; LI-COR, Lincoln, NE), the membrane was washed again and subjected to 
fluorescence detection at 800 nm using Odyssey Scanner (LI-COR). Bands in western bolt were 
analyzed using image studio lite software (LI-COR). 
 
Results  
The B+FB4 culture (basal media B, feed FB, seeding density at 4×10
5
 viable cells/ml) is the 
proprietary first-generation upstream process developed by Symphogen with optimal process 
parameter fitting with media B and feed FB for most of the IgG-producing cell lines generated by 
Symphogen. During in-house upstream optimization, we found media A with feed FA has 
potentially better media capacity for cell growth and antibody production in some cell lines if the 
cell culture starts at a suitable seeding density (data not shown). Here, we test the A+FA4 (basal 
media A, feed FA, seeding density at 4×10
5
 viable cells/ml), A+FA8 (basal media A, feed FA, 
seeding density at 8×10
5
 viable cells/ml) and B+FB4 cultures in order to demonstrate how the 
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nutrients (glucose and amino acids) were used differently during the fed-batch culture and what the 
IgG titer and glycosylation quality were in relation to that. 
Culture behavior and IgG production  
Culture behavior and IgG production constitute essential information for assessing media, feeds and 
overall upstream process performance. Figure 1 shows the effect of different upstream processes on 
growth, metabolism and IgG production for two model cell lines 1030 and 4384. In general, the 
durations of A+FA4 and A+FA8 cultures were slightly shorter than the B+FB4 culture. Notably, the 
A+FA8 culture resulted in faster cell growth and increased the integral of viable cells (IVC) for 
either cell line compared to the B+FB4 culture. More specifically, in Figure 1 A, when using the 
B+FB4 cultivation condition for the 1030 and 4384 cell lines, the peak viable cell concentrations 
were about 5 and 15 x 10
6
 cells/ml on day 11, respectively. In contrast, the peak viable cell densities 
were about 15 and 20 x 10
6
 cells/ml already on day 9 in the A+FA8  culture for the 1030 and 4384 
cell line, respectively. Interestingly, the A+FA4 culture did not exhibit any significant improvement 
on cell growth compared to the B+FB4 culture. Decline in viability occurred earlier and faster in the 
A+FA4 and A+FA8 cultures than in the B+FB4 culture (Figure S1 A). For either the 1030 or 4384 
cell line, the A+FA8 culture lead to considerably higher IgG production than the other cultures, as a 
result of both high cell growth and high specific productivity of  IgG (Figure 1 B). 
Although the different cultivation conditions are observed to influence specific IgG productivity 
(qp), the average qp of each cell line is relatively constant and calculated to be 40.7 pg/cell/day for 
1030 and 14.2pg/cell/day for 4384, as seen in Figure S3.  
As a consequence of consumption and feeding, glucose concentration fluctuated at slightly higher 
level in the A+FA8 culture compared to the B+FB4 culture. Also, quite noticeably, glucose largely 
accumulated during the A+FA4 culture (Figure 1 C). The accumulation of glutamine after the 
temperature shift in the A+FA4 culture reached 3.5 mM at harvest. Additionally, the concentration 
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of glutamine was around 1 - 2mM before feeding in the A+FA8 culture for both cell lines compared 
to around 0 - 1mM in the B+FB4 culture (Figure 1 C). Glutamate was generally maintained at a 
higher concentration before feeding in the A+FA8 culture (around 3 - 6mM) than in the B+FB4 
culture (around 2 - 4mM) throughout the fed-batch process (Figure 1 E). The average specific 
glucose and glutamine consumption rates from day 7 to harvest were found to be generally higher in 
the A+FA8 culture than in the B+FB4 culture for both cell lines (Figure 1 D&E).  
In terms of by-product formation, the accumulation of lactate in the A+FA8 culture was higher than 
that in the B+FB4 culture for both cell lines (Figure 1 F). In the A+FA4 culture, both lactate 
accumulation and its average specific production rate were particularly high, which may due to the 
high glucose concentration in this culture (Figure 1 F). Accumulation of NH4
+
 in the A+FA8 
culture was lower than that in the B+FB4 culture for both cell lines from day 5 to day 11 (Figure 1 
G). However, in the A+FA4 culture, the accumulation of NH4
+
 increased dramatically from 2mM 
up to 10mM during the culture, which also demonstrated a particularly high average NH4
+
 specific 
production rate (Figure 1 G).  
Amino acid and glucose metabolism  
To further understand the culture differences among the cultivation conditions and cell lines tested, 
the concentrations and specific consumption rates of amino acids and glucose have been assessed.  
In general, amino acid concentrations for 4384 cells were more stable in the A+FA8 culture than in 
the B+FB4 culture between day 5 and day 13 (Figure 2 A). Specifically, amino acids such as Asp, 
Ser, Gly, Val, Met, Ile, Leu, Lys, Arg, and all the aromatic amino acids (Tyr, Phe, His and Trp) 
have a clear decline from day 11 onwards in the B+FB4 culture. However, Ala accumulated in both 
A+FA8 and B+FB4 cultures from day 5 to day 13. The majority of amino acids have higher 
concentration on days 5, 9, 11 and 13 in the B+FB4 culture, apart from Glu and Gln on days 5, 9, 
11 and 13 and Cys, Val and aromatic amino acids (Tyr, Phe, Trp) on days 11 and 13. Interestingly, 
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the specific amino acid consumption rates are very much dependent on the concentration of 
corresponding amino acids in the culture. It was indicated by the fact that the specific amino acid 
consumption rates (except Glu, Gln and Ala) were higher from day 5 to day 13 in the B+FB4 
culture. Conversely, the specific glucose consumption rate was always higher in the A+FA8 culture 
from day 5 to day 13 (Figure 2 B&C).  We also found that the specific consumption rates of amino 
acids in the B+FB4 culture in early stationary phase (day 9 - 11) were higher than in growth phase 
(day 5 - 9) and late stationary phase (day 11 - 13). Conversely, the specific consumption rates of 
amino acids (except Glu, Gln, Ala, Cys, Tyr, HYP and ABU) in the A+FA8 culture are lower in 
early stationary phase (day 9 - 11) than in growth phase (day 5 - 9) and late stationary phase (day 11 
- 13).  Furthermore, the specific glucose consumption during the cell culture declined after the 
temperature shift (day 5) in the B+FB4 culture but was stable in the A+FA8 culture. 
Nucleotide sugar metabolism 
Nucleotide sugars are the donors of sugar chain elongation reactions in glycosylation; they are 
therefore thought to be one of the major factors that affect the final glycopatterns of the IgG. As 
shown in Figure 3, nucleotide sugars measured in this study were synthesized from glucose through 
two pathways:  the UDP-Glc/UDP-Gal/UDP-GlcA pathway and the UDP-GalNac/UDP-GlcNac 
pathway. In general, there was considerable accumulation of UDP-GlcNAc and UDP-GalNAc 
during the culture. In addition, their concentration was cell line-dependent (higher in 1030 cell line 
than in 4384 cell line under both cultivation conditions), and both species in 1030 cell lines were 
more sensitive to cultivation condition changes. 
Interestingly, the accumulation of UDP-GalNAc, UDP-GlcNAc and UDP-GlcA has a rather similar 
trend. Conversely, UDP-Gal and UDP-Glc accumulate to rather lower concentrations compared to 
UDP-GlcNAc and UDP-GalNAc, exhibiting similar profiles. Furthermore, their concentration was 
both cell line-dependent (higher in 1030 cell line than in 4384 cell line in either cultivation 
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condition) and cultivation condition-dependent (higher in A+FA8 culture than B+FB4 culture for 
either cell line).  
Abbreviated reaction network of glycosylation pathway 
An abbreviated reaction network is shown in Figure 4 illustrating the sequence of reactions that 
occur to produce the IgG-bound glycans that were identified in this work.  
Glycosylation of IgG 
Intact mass analysis was carried out mainly to provide relative quantification of glycan 
combinations at the N-glycosylation sites of the IgG.  Table I shows the glycan combinations on the 
IgG and their molecular weights that can typically be resolved from the mass spectrum. As shown 
in Figure 5, the A+FA8 and A+FA4 cultures led to a lower amount of relatively immature 
glycoform combinations (Man5/Man5, Man5/A1G0F and A1G0F/G0F) but higher amounts of 
relatively mature glycoform combinations (G0F/G1F, G1F/G1F or G0F/G2F and G1F/G2F) than 
the B+FB4 culture. Particularly, the Man5/Man5 combination from the A+FA8 culture was less 
than the detectable level of the analytical method used. We also noticed that the 4384 cell line 
produced more relatively immature glycoform combinations than the 1030 cell line in both A+FA8 
and B+FB4 cultures. The results were confirmed by glycoprofiling using instant AB labeling, an 
analysis providing higher resolution (Figure 6). As shown in Figure 6 A and B, the distribution for 
all cultures ranges from immature glycan structures such as Man7 to highly processed structures 
such as the G2FS1. The most abundant glycans were found to be G0F, G1F, Man5 and A1G0F. 
More Man5, G1F, G2F and G2FS1 were produced by 4384 cell line than 1030 cell line in the same 
cultivation condition. However, cell line 1030 produces more Man7 than cell line 4384, regardless 
of the cultivation condition. Furthermore, the A+FA8 culture gives rise to less Man5 and A1G0F, 
but more G1F and G2F than the B+FB4 culture. 
Western Blot analysis of GnT1 and UDP-GlcNAc transporter   
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1030 and 4384 cell pellets from day 2 and day 11 of the A+FA8 and B+FB4 cultures were collected 
for western blot analysis (Figure S2). The expression levels of GnT1 and UDP-GlcNAc transporter 
were analyzed with the purpose of understanding the very first steps of the glycan chain elongation 
reaction in the Golgi, in which UDP-GlcNAc is transported into the organelle and then added onto 
the Man5 glycan structure.  All measurements were first normalized to the internal standard β-Actin 
and further normalized to the condition of the 1030 cell line in the A+FA8 culture on day 2. In 
Figure 7, the expression of GnTI at both time points seems to be cultivation condition-independent 
for 1030 cells. However, a clear difference can be observed for UDP-GlcNAc transporter 
expression in 1030 cells. Culture 1030 A+FA8 shows basal levels of UDP-GlcNAc transporter 
expression on day 2, which then decrease by ~50% by day 11. In contrast, culture 1030 B+FB4 
shows slightly low level at day 2, which increases dramatically (~2-fold) by day 11. Expression 
profiles for both GnT1 and UDP-GlcNAc transporter were similar for the 4384 cell line, regardless 
of cultivation conditions. We also noticed that the level of GnT1 was lower in the B+FB4 culture at 
both time points than in the A+FA8 culture.  
 
Discussion 
The understanding of how different nutrients were consumed for different cell activities, 
specifically cell growth, metabolism and protein production, provides crucial insight for media and 
process optimization. Our data indicate that faster cell growth, higher IVC and IgG production, and 
more mature glycopatterns can be obtained as the result of more balanced amino acid concentration 
in the culture and higher glucose consumption rate when we transition from the B+FB4 to the 
A+FA8 culture for both 1030 and 4384 cell lines. A number of important factors that correlated 
with the cell growth, specific productivity and glycosylation have been identified in this study. 
Oxidative metabolism and by-product formation in correlation with cell growth  
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In the A+FA8 culture, higher glucose consumption compared to the B+FB4 culture implies that 
glucose is the major source for energy gain, despite leading to higher lactate levels. It is probably 
also the main reason why cells in A+FA4 media grow faster and to higher cell density. We have 
also noticed that more lactate was consumed from day 5 to 11 in the B+FB4 culture. This 
observation agrees with previous CHO metabolic flux studies that report that exponential growth 
phase is characterized by lactate production and high glycolysis rate and TCA flux, whereas in 
stationary phase cells demonstrate lactate consumption, lower glycolysis rate and TCA flux (Ahn 
and Antoniewicz 2011; Carinhas et al. 2013). In contrast, we found higher specific glucose 
consumption rates and higher lactate, Gly and Ala specific production rates in stationary phase (day 
9 to 11) than in late growth phase (day 5 to 9) of the A+FA8 culture. In fact, leaking from 
glycolysis is thought to balance the cytosolic NAD/NADH level, so the capacity of the TCA cycle 
is not exceeded (Mulukutla et al. 2012). When comparing B+FB4 with A+FA8 culture, positive Ala 
specific production rate, higher Ile and Leu specific consumption rates and higher specific 
consumption rates of Glu and its possible supplier Pro, His, and Arg indicate higher transamination 
activities of cells (Chen and Harcum 2005; Schmelzer and Miller 2002) and thus more 
intermediates for entering the TCA cycle in B+FB4 culture. Faster accumulation of NH4
+
 in the 
growth phase of the B+FB4 culture also provides evidence for oxidative metabolism by means of 
converting Gly, Ser and Cys to pyruvate and glutamate to α-ketoglutarate. The high accumulation 
of NH4
+
, which is thought to inhibit cell growth (Altamirano et al. 2013), could also be one of the 
important downsides of the B+FB4 culture in contrast to the A+FA8 culture. In the A+FA4 culture 
as an extreme case, very high lactate and NH4
+
 concentrations inhibited cell growth as a 
consequence of unbalanced nutrient supply to cell activities. Interestingly, Leu has previously been 
reported to have a detrimental effect on cell growth (Gonzalez-Leal et al. 2011). Therefore, 
reducing its concentration as in the A+FA8 process appears to be beneficial. It is also worth 
           
19 
 
mentioning that the different behaviors with respect to specific glucose consumption rate from day 
5 onwards in the A+FA8 and B+FB4 cultures might not be a direct response to temperature shift 
and change in growth rate. This would be consistent with previous results showing that the specific 
glucose consumption is not affected by either temperature reduction or low specific growth rate 
(Vergara et al. 2014). A possible explanation for such a difference might be that the requirement of 
glucose and the redistribution of carbon flux for biomass and lactate accumulation in different 
growth phases depended on the nutrient concentrations in the culture. 
Amino acid metabolism in correlation with specific productivity 
Ser and Leu were the two amino acids with the highest consumption rates in the B+FB4 culture. 
The fast consumption of Ser and Leu can be attributed to their abundance in the amino acid 
composition of the produced 4384 antibody (Table SI). It is also reasonable to find that Arg, which 
has been reported to have a negative effect on mAb production in CHO DG44 cell culture 
(Gonzalez-Leal et al. 2011), is present at lower concentrations in A+FA8 culture than B+FB4 
culture. More amino acids consumed entered the catabolic process in B+FB4 culture than in A+FA8 
culture, in order to complement the energy gain from glucose. Therefore, the building blocks for 
IgG production may be less and the specific productivity in B+FB4 culture may thus be negatively 
affected.  
Factors that affect glycosylation 
Here, we also present the mAb Fc N-glycosylation distributions resulting from different cell lines 
cultured in two media with appropriately formulated feeding strategies. In order to identify the 
cause for the observed differences in glycan profiles, the mechanisms that determine the 
glycosylation process must be considered. 
Product-associated mechanisms 
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The first property that controls N-glycosylation is the accessibility of the protein-bound glycan for 
action by glycosidases and glycosyltransferases. For example, the limited presence of galactose and 
sialic acid on the Fc glycans of mAbs has, in some cases, been attributed to these effects (Hills et al. 
2001; Wormald et al. 1997). This limitation depends solely on the tertiary and quaternary structure 
of the recombinant protein, and is independent of metabolic and protein expression effects. 
Resident protein-associated mechanisms 
The second mechanism that influences glycan processing is the abundance and activity of 
glycosylation-associated Golgi resident proteins relative to the specific productivity of the 
recombinant protein. The Golgi resident proteins most closely involved in protein glycosylation are 
nucleotide sugar transport proteins and glycosylation enzymes (glycosidases and 
glycosyltransferases). Gene expression of these Golgi resident proteins has been reported to vary 
during cell culture (Pacis et al. 2011; Wong et al. 2010a) and overexpression of glycosyltransferases 
(Umana et al. 1999; Weikert et al. 1999) and NS transport proteins (Wong et al. 2006) has been 
used to control or remodel the glycosylation patterns of therapeutic proteins produced in CHO cells. 
Additional reports have suggested that activity and localization of Golgi resident proteins may be 
influenced by certain process conditions, such as ammonia accumulation and concomitant changes 
in culture pH. Specifically, elevated culture pH has been associated with reduced 
galactosyltransferase and sialyltransferase activities (Gawlitzek et al. 2000; Muthing et al. 2003; 
Yoon et al. 2005) and mislocalization of glycosyltransferase enzymes within the Golgi apparatus 
(Rivinoja et al. 2009). In addition, pH has also been reported to impact UDP-GlcNAc transport into 
the Golgi apparatus by modifying the ionisation state of UMP, which is the anti-port substrate used 
by the UDP-GlcNAc transport protein (Waldman and Rudnick 1990). 
Metabolic mechanisms 
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The third mechanism that determines glycan processing is the availability of nucleotide sugars 
within the Golgi apparatus lumen. Addition of monosaccharides to the protein-bound glycans 
requires nucleotide sugars as co-substrates. When these species are in low abundance in the Golgi 
lumen, the extent of glycosylation reactions decreases. Reduced nucleotide sugar concentration 
within the Golgi apparatus may result from limited transport of these species into the Golgi 
apparatus (Weikert et al. 1999; Wong et al. 2006) or from nutrient limitations during their 
biosynthesis (Kochanowski et al. 2008). Specifically, availability of UDP-GlcNAc has been 
reported to be closely linked with glutamine availability during cell culture (Chee Furng Wong et al. 
2005; Nyberg et al. 1999) and strategies to increase the availability of this NS have relied on 
supplementing culture media with glucosamine and uridine (Baker et al. 2001; Hills et al. 2001). 
Similarly, availability of UDP-Gal has been linked with glucose metabolism and efforts to control 
galactosylation of therapeutic proteins have relied on supplementing cell cultures with uridine, 
manganese and galactose (Grainger and James 2013; Gramer et al. 2011). 
When analysing our data for recombinant protein glycosylation within this mechanistic context, we 
see that the presence of certain glycans results from both resident protein availability and metabolic 
effects. The relative abundance of Man7 correlates with the specific productivity of each cell line. 
Cell line 1030, which has the highest average qp (see Figure S3), produces more Man7 (up to 2.1% 
± 0.25%) than cell line 4384 (up to 0.43% ± 0.08%). It is possible that this occurs because the 1030 
cells have insufficient alpha mannosidase II (ManII) availability to cope with their higher qp.  
In contrast to the Man7 glycan, presence of Man5 can occur because of low abundance or activity 
of Golgi resident proteins (UDP-GlcNAc transporter and GnTI) or low intracellular availability of 
UDP-GlcNAc. Despite similar UDP-GlcNAc transporter expression levels, 4384 cells produce 2.2-
fold ± 0.2 (p=0.000022) more Man5 in B+FB4 culture than in A+FA8 culture (Figure 6). This 
indicates that, for this cell line, accumulation of the Man5 glycan is likely due to the bottleneck in 
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availability of UDP-GlcNAc and expression of GnT1. This is further confirmed by Figure 3 where 
the 4384 cell line was found to have extremely low intracellular UDP-GlcNAc concentration and 
Figure 7 where this cell line exhibited lower expression level of GnT1 on both day 2 and day 11 in 
B+FB4 culture. We must emphasize that low intracellular nucleotide sugar concentration may occur 
due to low levels of biosynthesis or high levels of consumption. Given the low GlcNAc occupancy 
(Figure 8 A) and high amount of Man5 that accumulates for culture 4384 B+FB4 compared to those 
of culture 4384 A+FA8, it is likely that the low intracellular UDP-GlcNAc concentration for the 
former is due to low biosynthesis of this nucleotide sugar, whereas the low UDP-GlcNAc 
concentration observed for 4384 A+FA8 is likely due to high consumption of this nucleotide sugar. 
Limited biosynthesis of UDP-GlcNAc in culture B+FB4 is substantiated by the low extracellular 
glutamine availability in this culture (Figure 1 D). Limited availability of this nutrient has been 
widely reported to limit UDP-GlcNAc biosynthesis (Chee Furng Wong et al. 2005; Kochanowski et 
al. 2008; Nyberg et al. 1999). 
Cell line 1030 exhibits rather different behaviors. In culture B+FB4, 1030 cells produce 81.1% ± 
3.5% (p<0.0001) more Man5 and 8.3% ± 0.9% (p=0.00055) lower overall GlcNAc occupancy than 
in the A+FA8 culture. This contrasts heavily with the intracellular UDP-GlcNAc concentration data 
(Figure 3), where the culture that generates lowest GlcNAc occupancy and highest Man5 secretion 
exhibits higher UDP-GlcNAc availability. Therefore, UDP-GlcNAc concentration may not be the 
limiting factor for the glycosylation processing in this cell line. It is also correlated with previous 
findings that feeding GlcNAc, although increased intracellular concentration of UDP-GlcNAc 
(Wong et al. 2010b), could not decrease the level of Man5 or A1G0F of the IgG produced 
(unpublished data). High UDP-GlcNAc accumulation, high Man5 secretion and a lower overall 
GlcNAc occupancy can occur if the nucleotide sugar is being consumed at a lower rate than that at 
which it is being produced. Reduced consumption of UDP-GlcNAc may be attributed to insufficient 
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expression of GnTI or UDP-GlcNAc transporter. However, Figure 7 shows that GnTI is expressed 
at similar levels in both cultivation conditions for cell line 1030, suggesting that enzyme expression 
may not be limiting. We also see that cell line 1030 in the B+FB4 culture presents a 2-fold increase 
in expression of the UDP-GlcNAc transporter transporter by day 11 of culture despite having 
slightly lower expression of this transporter on day 2. This suggests that availability of UDP-
GlcNAc transporter is also non-limiting. With this analysis, the only remaining causes for reduced 
UDP-GlcNAc consumption involve the activity of GnTI or UDP-GlcNAc transporter. We also 
found that high extracellular ammonia accumulation in this cell line correlates with low GlcNAc 
occupancy and high Man5 secretion. Previous reports have proposed that ammonia accumulation 
may increase the pH within the Golgi apparatus, thus inhibiting the activity of glycosylation 
enzymes (Borys et al. 1994; Gawlitzek et al. 2000). It has also been reported that increased Golgi 
pH causes mislocalization of glycosyltransferases (Rivinoja et al. 2009) and impacts UDP-GlcNAc 
transport into Golgi by modifying the ionisation state of UMP, which is the anti-port substrate used 
by UDP-GlcNAc transporter (Waldman and Rudnick 1990).  
Similarly to GlcNAc occupancy, the addition of galactose to mAb Fc glycans depends both on 
glycosyltransferase availability and intracellular nucleotide sugar concentration. In addition, 
however, low abundance of galactose on mAb Fc glycans has also been associated with decreased 
accessibility of GalT to the oligosaccharides present on this site (Hills et al. 2001; Wormald et al. 
1997). Figure 8 B shows that cell line 1030 produces similar levels of galactose occupancy under 
both tested cultivation conditions. In contrast, culture 4384 A+FA8 leads to 38.4% ± 16.4% 
(p=0.023) higher galactose occupancy than culture B+FB4 with the same cell line, indicating that 
for 4384 cells, galactosylated glycan production is cultivation condition-dependent. Despite this, the 
data shows that, on average, 4384 cells generate higher galactosylation.  
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This may be attributed to the lower qp of these cells, which could result in higher relative 
availability of galactosylation-associated Golgi resident proteins (UDP-Gal transporter and GalT).  
Despite having no observable difference in galactosylation, the intracellular profiles of UDP-Gal for 
1030 cells are different. Figure 3 shows that 1030 A+FA8 culture has higher intracellular UDP-Gal 
concentration compared to the 1030 B+FB4 culture. Because both these cultures have similar 
specific mAb productivities and similar levels of galactosylation, it is likely that the reduced UDP-
Gal concentration in culture 1030 B+FB4 is due to reduced biosynthesis of this nucleotide sugar 
and not to higher consumption. Indeed, when comparing both cultures, we see that culture 1030 
B+FB4 presents lower extracellular glucose concentration, lower specific glucose consumption rate 
and considerably lower extracellular Gln availability (Figure 1 C&D). Reduced intracellular UDP-
Gal concentration may occur due to all these factors. Broadly, UDP-Gal is produced using two 
building blocks: the carbohydrate backbone (in this case glucose-derived galactose) and the 
nucleotide component (UTP), which is the product of pyrimidine metabolism. Low glucose 
availability and specific consumption would correlate with lower availability of the galactose 
backbone of UDP-Gal. It has been recently confirmed experimentally that differences of glucose 
concentration in cell culture and its consumption can affect the level of protein galactosylation (Liu 
et al. 2014). Similarly, low glutamine availability has been reported to negatively impact 
intracellular concentration of UTP (Nyberg et al. 1999). It is no coincidence that the most 
successful strategies in increasing UDP-Gal pools for improved recombinant protein galactosylation 
have relied on addition of galactose and uridine, a direct precursor of UTP (Grainger and James 
2013; Gramer et al. 2011). 
Intracellular UDP-Gal concentrations are also cultivation condition-dependent for 4384 cells. 
Similarly to 1030 cells, the A+FA8 culture yields higher intracellular UDP-Gal than B+FB4 for 
4384 cells. This difference is also likely due to reduced glutamine availability and specific glucose 
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consumption associated with the B+FB4 culture. Given the difference observed in the intracellular 
UDP-Gal profile, it is possible to attribute the reduction in mAb Fc glycan galactosylation to lack of 
UDP-Gal availability. Finally, the impact of ammonia accumulation must be discussed to confirm 
that reduced UDP-Gal biosynthesis is responsible for low galactosylation levels. We see that the 
culture with lower galactose occupancy (4384 B+FB4) reaches a peak extracellular ammonium 
concentration of about 5mM (Figure 1 G). This value is low when considering that previous 
publications have observed negative effects on galactosylation at extracellular ammonia 
concentrations above 10mM (Borys et al. 1994; Chen and Harcum 2005; Gawlitzek et al. 2000), 
making ammonium effects unlikely and confirming that low galactose occupancy in this culture is 
likely dominated by low biosynthesis of UDP-Gal. 
In conclusion, to the best of our knowledge this is the first study that provides an integrative 
understanding of cell growth, metabolism, IgG titer and glycosylation in correlation with the 
dynamics of glucose and amino acid consumption when optimization of fed-batch culture such as a 
change in media and feed occurs. Our results demonstrate that the effect of media and process 
optimization on glycosylation should be understood from case to case and results from the interplay 
of the protein processing rate, cell metabolism, and expression and activity of Golgi resident 
proteins. Given the multiplicity of mechanisms involved, systems biology approaches could in the 
future contribute to the understanding of protein glycosylation and further aid attempts for 
glycoform control. 
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Table I.  Typical glycan combinations on the IgG resolved from intact mass. MWIgG-NG/NG is the 
molecular weight of the non-glycosylated (NG) IgG in question. # Detectable only in high abundance. 
Glycan combinations on the IgG Detected intact mass of IgG (Da) 
NG/NG MW IgG-NG/NG 
#
 
G0F/NG MW IgG-NG/NG +1445 
#
 
Man5/Man5 MW IgG-NG/NG +2434  
Man5/A1G0F MW IgG-NG/NG + 2458  
A1G0F/A1G0F MW IgG-NG/NG + 2482 
A1G0F/G0F MW IgG-NG/NG + 2687 
G0F/G0F MW IgG-NG/NG + 2891 
G0F/G1F MW IgG-NG/NG + 3053 
G1F/G1F or G0F/G2F MW IgG-NG/NG + 3215 
G1F/G2F MW IgG-NG/NG + 3377 
G2F/G2F MW IgG-NG/NG + 3539 
 
Figure legends 
Figure 1. Comparison of five fed-batch cultures with different cell lines and cultivation conditions. 
Viable cell density and integral of viable cells (IVC) vs. IgG titer are presented in (A) and (B), 
respectively. Time courses of Glucose (C), Glutamine (D), Glutamate (E), Lactate (F) and Ammonia 
(G) concentrations are also shown. The error bars correspond to one standard deviation calculated from 
duplicate experiments. In (C), (D) and (E) the data points from B+BA4 culture and A+FA8 culture on 
days 3, 4, 6, 8, 10 and 12 and from A+FA4 culture on days 3, 4, 6, 8, 10, 11 are unmeasured pseudo 
points calculated by assuming the consumption rate is constant between the measured points. Average 
of specific consumption/production rate of certain metabolite was also calculated based on specific 
consumption/production rate of certain metabolite on each measured time point from day 7 to the 
harvest (same color codes are used for indicating the cultivation conditions). 
Figure 2. Glucose and amino acids metabolisms of 4384 cell line in A+FA8 and B+FB4 cultures. (A) 
Amino acid concentrations on day 5, 9, 11, 13 in the cell culture before feeding. All amino acids were 
measured by free amino acid analysis, except glutamine, which was measured by Bioprofile 100 plus. 
Glutamine, threonine and asparagine eluted as one peak and their concentration cannot be resolved in 
the chromatogram of the free amino acid analysis. (B) Specific consumption rates of amino acids: from 
day 5 after feeding to day 9 before feeding (left point), from day 9 after feeding to day 11 before 
feeding (middle point), from day 11 after feeding to day 13 before feeding (right point). (C) Specific 
consumption rate of glucose.  
Figure 3. Intracellular nucleotide sugar analysis of cell lysates from fed-batch. Nucleotide sugar 
synthesis typically starts from degradation of glucose through glycolysis, in which glucose converts 
into glucose-6-phosphate and fructose-6 phosphate. Glucose-6-phosphate becomes UDP-glucose 
(UDP-Glc), UDP-galactose (UDP-Gal) and UDP-glucuronic acid (UDP-GlcA) through a series of 
enzymatic reactions. On the other hand, fructose-6 phosphate supplying further glycolysis and TCA 
cycle for energy gain can also be directed into two major nucleotide sugar synthesis pathways. One can 
generate UDP-glucosamine (UDP-GlcNAc) and UDP-galactosamine (UDP-GalNAc). The other one 
can produce GDP-mannose (GDP-Man) and GDP-fucose (GDP-Fuc). Galactose, mannose, fructose as 
well as other sugars illustrated in the figure with red circle can also be used as substrates for nucleotide 
sugar synthesis other than glucose. Nucleotide sugars measured in this study were shown in blue box. 
Figure 4. Simplified reaction scheme for IgG Fc N-glycosylation. The network begins with a nine 
mannose oligosaccharide structure, which is sequentially cleaved by α -mannosidase I (ManI) until a 
five mannose structure is produced (Man5). An N-acetylglucosamine residue (GlcNAc) is then added 
to the Man5 glycan by action of the α-1,3-mannosyl-glycoprotein 2-β-N-acetylglucosaminyltransferase  
(GnTI). After this point, the reaction scheme diverges into two branches, depending on the order in 
which the reactions occur. Regardless of the order, after the GnTI-catalysed reaction, additional 
mannose residues are removed by α -mannosidase II (ManII) to yield the A1G0 glycan. Subsequently, 
a fucose residue is added by the 6- α -fucosyltransferase enzyme (FucT) to produce A1G0F, followed 
by addition of a second GlcNAc residue by α-1,6-mannosyl-glycoprotein 2-β-N-
acetylglucosaminyltransferase (GnTII) to generate the G0F glycan. The reaction sequence concludes 
with addition of galactose and sialic acid residues to each arm of the biantennary glycan by means of β-
1,4 galactosyltransferase (β -GalT) and α-2,6/α-2,3 sialyltransferase (SiaT), respectively. Addition of 
these monosaccharides produces the G1F, G2, G2F and G2FS1 glycans. 
Figure 5. Relative abundance of glycan combinations of IgG detected by intact mass analysis. 
Figure 6. Analysis of IgG glycosylation by Instant-AB labelled glycoprofiling. (A) and (B) Glycan 
distribution as determined by HPLC. 
Figure 7. Quantification of intracellular GnT1 and UDP-GlcNac Transporter levels by western bolt. 
Figure 8. Intracellular NSD concentration and average monosaccharide occupancy on glycans. The 
percentage of GlcNAc occupancy in all measured glycans is presented in (A) and occupancy of 
galactose is presented in (B). GlcNAc occupancy was calculated assuming that 100% occupancy 
involves two moles of GlcNAc being added to all glycans in Golgi: GlcNAcocc = (2*G0F + 2*G1F + 
0*Man5 + 1*A1G0F + 1*A1G0 + 2*G2 + 0*Man7 + 2*G2FS1 + 2*G2F)/2. Similarly, galactose 
occupancy was calculated assuming that 100% corresponds to two moles of galactose being added to 
all glycans within the Golgi: Galocc = (0*G0F + 1*G1F + 0*Man5 + 0*A1G0F + 0*A1G0 + 2*G2 + 
0*Man7 + 2*G2FS1 + 2*G2F)/2. 
